Charged Alpha Stock Encyclopedia

argenx SE (ARGX) Q2 2026 — argenx (ARGX), the Dutch-Belgian immunology biotech behind the blockbuster VYVGART franchise (efgartigimod, an FcRn blocker), reported a strong Q2 2026: global product net sales of $1.5B (+60% YoY, +17% QoQ), operating profit more than doubled to $494M, net profit rose 93% to $472M, and diluted EPS nearly doubled to $7.32. The company is now solidly profitable and cash-generative — H1 operating cash flow flipped to +$0.7B (from -$0.4B) — with $5.2B cash and no debt. It expanded the U.S. VYVGART label to all gMG serotypes, is ramping CIDP, and has near-term pipeline readouts (ALKIVIA myositis in 3Q26, EMPASSION/empasiprubart in 4Q26). The stock jumped ~7% to ~$910, ~4% below its $953 high. At ~30x forward earnings our owner-earnings DCF lands a base fair value near $1,090 (~20% upside), with the pipeline-compounder path past $1,350. Our call: BUY, 3/5 — aligned with the Street's Buy (~$1,124 avg target), disciplined on the one-molecule concentration.

argenx is one of biotech's rare double threats — a company that is BOTH hyper-growth AND already profitable. Its FcRn-blocking antibody efgartigimod, sold as VYVGART and VYVGART Hytrulo, has become one of the fastest drug launches in history, and Q2 2026 showed the model inflecting: product net sales of $1.5B (+60% YoY, +17% QoQ), operating profit up 146% to $494M, net profit up 93% to $472M, and diluted EPS of $7.32 (nearly double). The engine is indication expansion — one molecule approved in more and more autoimmune diseases: generalized myasthenia gravis (now all serotypes, including seronegative), CIDP (ramping fast via the subcutaneous Hytrulo), with ocular MG, myositis, ITP, Sjogren's and Graves' behind it. The balance sheet is a fortress: $5.2B cash, no debt, and H1 operating cash flow that swung positive to +$0.7B, so the entire 10-molecule pipeline is self-funded. The debate isn't quality — it's price. At ~$910 (up ~7% on the print, near its $953 high) the stock trades ~30x forward earnings and ~9x sales. But because argenx now generates real cash, we can value it on owner earnings: our base-case DCF (9% quality-adjusted discount, franchise path) lands near $1,090 — about 20% above the price — with the pipeline-compounder path pointing past $1,350. Our call: BUY, 3/5. It's a wonderful, first-in-class franchise with genuine optionality and a fair (not fat) margin of safety. Why only a 3? Because a single molecule still carries essentially all the revenue at a premium multiple, and J&J's nipocalimab is circling. We're aligned with the Street's bullish Buy (~$1,124 average target, 31 of 36 analysts) — but we get there with a disciplined DCF, not momentum. Own it for the quality, add on weakness toward the mid-$800s, and watch the ALKIVIA and EMPASSION readouts. Not financial advice.

THE CALL: BUY (3/5, A RARE PROFITABLE-GROWTH BIOTECH — QUALITY WITH REAL OPTIONALITY, AT A FULL BUT FAIR PRICE) — base-case value ~$1090 vs ~$910 today.

What to watch: clean wins from the near-term pipeline readouts — the ALKIVIA myositis study (3Q26) and the EMPASSION/empasiprubart trial (4Q26) — plus continued CIDP ramp, which would confirm the platform thesis and justify paying up further and an upgrade; the risk to respect is a pipeline miss, an unexpected VYVGART safety signal, or J&J's nipocalimab taking real share in gMG, which at ~30x earnings on a one-molecule revenue base could re-rate the stock hard

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

West Pharmaceutical Services (WST) Q2 2026 — West Pharmaceutical Services (WST), the near-monopoly maker of the elastomer stoppers, seals and delivery devices inside injectable drugs, reported a strong Q2 2026: adjusted EPS of $2.37 beat the ~$2.08 estimate (+29% YoY) on net sales of $872.3M (+13.8% reported, +12.7% organic), as High-Value Product Components (+19%) and Delivery Devices (+30%) rode the biologics and GLP-1 boom. Management RAISED full-year guidance — adjusted EPS to $8.85–$9.05 and sales to $3.35–$3.38B. The stock spiked to a record near $385 on the print, then faded to ~$364 (+1.6%). The catch: at ~41x forward earnings and ~50x free cash flow, even our optimistic compounder DCF lands near $290 — below the price. Our call: HOLD.

West Pharmaceutical Services is the quiet monopoly behind injectable medicine — the world leader in the elastomer stoppers, seals, plungers, syringes and wearable delivery devices that contain and deliver the drug inside almost every vial and pre-filled syringe on earth. It's the ultimate picks-and-shovels play on biologics and GLP-1 obesity drugs: once a component is validated into an FDA-approved injectable, it's regulated-in for a decade, so West wins no matter which drug wins. Q2 2026 was a genuinely strong quarter: adjusted EPS of $2.37 beat the ~$2.08 estimate (+29% YoY), net sales rose 13.8% to $872.3M (+12.7% organic), gross margin expanded to ~38%, and operating profit rose 16.5% to $179M. The engine was High-Value Products: HVP Components grew 19% to $424M (49% of sales) and HVP Delivery Devices jumped 30% to $131M, driven by biologics strength, EU Annex 1 upgrades, and growing GLP-1 elastomers — the destocking hangover of 2023–24 is finally over. Management RAISED full-year 2026 guidance across the board: adjusted EPS to $8.85–$9.05 (from $8.40–$8.75) and net sales to $3.35–$3.38B (~10–11% organic). The balance sheet is a fortress (net cash), and capex is rolling off from a ~$380M peak toward $250–275M, which should lift free cash flow toward $500M+. So the debate isn't quality — it's price. After a 60%+ run off the $224 low, WST trades near 41x forward earnings and ~50x free cash flow, and it faded a record-high pop on this clean beat. Even giving West full credit for the GLP-1 compounder path, our owner-earnings DCF lands fair value near $290 — roughly 20–25% below today's ~$364. A wonderful company with no margin of safety. Our call: HOLD, 3/5. We're more cautious than the Street's bullish ~$370 target (Buy, ~11 of 15 analysts) — and note West's own buyback averaged $258 a share this year, well below today's price. Own it for the quality, add on real weakness toward the high $200s, and watch the GLP-1 and biologics volumes. Not financial advice.

THE CALL: HOLD (3/5, A WONDERFUL MONOPOLY, PRICED FOR PERFECTION — A BEAT-AND-RAISE WITH NO MARGIN OF SAFETY) — base-case value ~$290 vs ~$364 today.

KEY METRICS:

- Adjusted EPS $2.37 beat ~$2.08 (+29% YoY); GAAP diluted EPS $2.15 (+18%)

- Net sales $872.3M, +13.8% reported / +12.7% organic

- Proprietary Products +16.6% to $722.6M (op profit +31%); West Vantage +2% to $149.7M (profit fell)

- HVP Components +19% to $424M (49% of sales); HVP Delivery Devices +30% to $131M

- FY2026 guidance RAISED: adj EPS $8.85–$9.05 (from $8.40–$8.75); sales $3.35–$3.38B (~10–11% organic)

- Q2 operating cash flow $214M, free cash flow $128M; net-cash balance sheet (~$233M)

- H1 2026 buybacks $454M at avg $258/share — well below today's ~$364

- Valuation ~41x forward EPS, ~50x FCF; our owner-earnings DCF fair value ~$290

What to watch: hard evidence the GLP-1 and biologics volume boom is long and durable — the high-value product mix and pricing sticking, delivery-device and elastomer growth compounding, and free cash flow marching past $500M as capex rolls off — which would justify the premium multiple and prompt an upgrade; the risk to respect is a repeat of the 2023–24 destocking cycle, where customers over-order and inventories bloat, which at ~41x earnings and ~50x free cash flow could re-rate the stock hard

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Nokia (NOK) Q2 2026 — Nokia (NOK, NYSE ADR) reported Q2 & Half-Year 2026 on July 23, 2026. Comparable operating profit rose 18% YoY to €434M — a beat vs the ~€382M LSEG consensus — with comparable operating margin up 70bps to 9.0% and net sales of €4.82B, +8% reported (+9% constant currency). But on a REPORTED basis Nokia posted an operating LOSS of €50M, a −1.0% margin, as it accelerated restructuring (now €800M of charges in 2026); reported diluted EPS was €0.00 vs comparable €0.07. The story was AI & Cloud: order intake hit a record €2.8B and sales to AI/cloud customers grew 105% (more than doubled), driving Network Infrastructure +12% (Optical Networks +20%, boosted by the 2025 Infinera acquisition; IP Networks +16%). But only ~half of that order intake converts to revenue within 12 months, and Nokia guided comparable operating profit 'largely flat' Q2→Q3 before a Q4 jump — management's own 'lumpy' caveat. The larger Mobile Infrastructure segment (55% of sales) grew just 6% with operating profit flat at €310M and margin slipping to 11.6%. Net cash was €2.78B (~$3.2B, only ~6% of market cap); the Board declared a €0.04/share dividend (~1.6% ADR yield). FY26 outlook: comparable operating profit €2.1–2.6B ('somewhat above midpoint'), Network Infrastructure net sales +12–14%, capex €800–900M. The ADR — which quadrupled off a $4 low to a $17.45 high on the AI-networking theme — has round-tripped back to ~$9.97 (−3% on the day, ~43% off its high). At ~18× EV/comparable-EBIT and ~25× comparable earnings, our EV/EBIT through-cycle frame lands fair value near $9.00 — modestly below today's price and well below the Street's BUY consensus and ~$17.5 average target. Our call: HOLD, 3/5 — deliberately more cautious than Wall Street.

Nokia spent the last two years as the market's favorite AI-networking comeback: the ADR quadrupled off a $4 low to a $17.45 high as Wall Street decided the old Finnish telecom-gear maker was a clean way to play the AI data-center buildout. Q2 2026, reported July 23, was supposed to be the vindication — and on the surface it was. Comparable operating profit jumped 18% to €434M, beating the ~€382M consensus; net sales grew 8% to €4.82B; and the headline number was electric: a record €2.8 billion of AI & cloud order intake, with sales to those customers more than doubling (+105%). Optical Networks (supercharged by the 2025 Infinera acquisition) grew 20% and IP Networks 16%. And yet the stock fell ~3% on the day and sits ~43% below its high. Why? Because the report has two very different profit numbers: strip away the 'comparable' polish and Nokia posted a REPORTED operating LOSS of €50M — a negative 1.0% margin — dragged down by €800M of accelerated restructuring. Dig further and the growth is narrower and lumpier than the headline: only about half the €2.8B order book converts within a year, management guided profit 'largely flat' into Q3, and the bigger half of the company — Mobile Infrastructure, 55% of sales — grew just 6% with flat profit and slipping margins. So the AI-datacenter engine is real, but it's one smaller segment inflecting while the majority sits still, funded by a thin ~€2.8B net-cash cushion (only ~6% of the market cap) and a small ~1.6% dividend. New CEO Justin Hotard (ex-Intel data-center chief) is doubling down — pushing capex to €800–900M and buying NXP's Arizona chip campus to make Nokia's own optical semiconductors — an Intel-style vertical-integration bet whose payoff is 2027–2028, not now. The honest question isn't whether AI demand is real (it clearly is) but whether it becomes durable, smooth, compounding profit — or stays a series of big, uneven, hard-to-model quarters the market has already handed a growth multiple. At ~18× EV/EBIT and ~25× comparable earnings, an EV/EBIT through-cycle frame lands fair value near $9 — modestly below today's ~$10 and far below the Street's BUY / ~$17.5 target. Our call: HOLD, 3/5 — real AI traction, already in the price, and we're deliberately more cautious than Wall Street. Not financial advice.

THE CALL: HOLD (3/5, REAL AI TRACTION, ALREADY IN THE PRICE — A FULL MULTIPLE ON ONE LUMPY GROWTH ENGINE) — base-case value ~$9.00 vs ~$9.97 today.

What to watch: proof the AI order surge is durable rather than lumpy — specifically REPORTED operating margin turning clearly positive as the €800M restructuring rolls off, and the €2.8B AI/cloud order book converting into smooth, compounding revenue (not another flat-then-lumpy quarter) — which would flip us to a buy; the risks that would turn us more negative are Mobile Infrastructure staying flat, order conversion slipping, or the capex-heavy Arizona/optical semiconductor bet swallowing the thin net-cash cushion, any of which would pull fair value toward the $8s

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Union Pacific Corporation (UNP) Q2 2026 — Union Pacific Corporation (UNP), North America's largest Class I railroad, reported RECORD Q2 2026 revenue of $6.86B (+12% YoY) with GAAP diluted EPS of $3.36 (+7%; adjusted $3.41, +13%), net income of ~$2.0B (+6%), and operating income of $2.76B (+9%) — a headline beat. But it was fuel-flattered: excluding fuel surcharge, freight revenue grew just +4% and total carloads only +2% (diesel +60% to $3.86/gal drove roughly two-thirds of the +12%). The operating ratio actually WORSENED 70 bps to 59.7% (management says fuel cost it 120 bps; ex-fuel the underlying improved, with record velocity and dwell). Intermodal jumped +26% but on just +4% volume. UNP RAISED full-year guidance to high-single-digit EPS growth, yet buybacks collapsed to $26M (from $2.7B a year ago) to fund its pending ~$85B acquisition of Norfolk Southern — 1.0 UP share + $88.82 cash per NSC share (~$320/share), $2.75B of claimed synergies, the first coast-to-coast single-line railroad — now under STB review (application accepted, then held in abeyance with a full environmental review and opposition ahead; targeted close early 2027). The stock hit an all-time high near $303 (~24x earnings, top of its 10-year range; market cap ~$180B). Our two-path owner-earnings DCF lands at ~$250 standalone / ~$340 if the merger closes; the regulatory-risk-weighted blend is ~$285 — about 6% below the price and roughly in line with the Street's ~$303 average target (a soft Buy, with ~1/3 of analysts at Hold; median $297). Our call: HOLD, 3/5 — an elite, best-in-class railroad priced for a transformational merger that isn't done. Not financial advice.

Union Pacific is the largest railroad in North America — an irreplaceable ~32,000-mile network across the western two-thirds of the U.S., a western duopoly with BNSF, the best operating ratio (~59%, where lower is better) and ~40% ROE among the Class I's. On July 23, 2026 it reported a record Q2: revenue $6.86B (+12% YoY), GAAP EPS $3.36 (+7%; adjusted $3.41), net income ~$2.0B, operating income $2.76B (+9%), and it RAISED full-year guidance to high-single-digit EPS growth. But strip out fuel and the quarter is only solid: ex-fuel-surcharge freight revenue grew just +4%, carloads +2%, and the operating ratio WORSENED 70 bps to 59.7% (diesel +60% to $3.86/gal drove ~two-thirds of the top-line growth and cost 120 bps of OR). Even intermodal's +26% came on +4% volume. The real reason the stock ran to an all-time high near $303 is a blockbuster deal: UNP's pending ~$85B acquisition of Norfolk Southern (1.0 UP share + $88.82 cash per NSC share; ~$2.75B synergies; the first true coast-to-coast railroad, 50,000 route miles across 43 states; UP holders own ~73%), which the Surface Transportation Board accepted and then held in abeyance, with a full environmental review and organized opposition ahead. A tell: buybacks collapsed to $26M (from $2.7B a year ago) to hoard cash for the deal. At ~24x earnings (top of its 10-year range), our two-path owner-earnings DCF is ~$250 standalone and ~$340 if the merger closes — a regulatory-risk-weighted blend of ~$285, about 6% below the price and roughly on top of the Street's ~$303 average target (a soft Buy; ~1/3 Hold; median $297). Our call: HOLD, 3/5 — a great railroad with no margin of safety, its upside resting on a merger the regulators just paused. Own it for the quality, add in the mid-$200s, and watch every STB filing. Not financial advice.

THE CALL: HOLD (3/5, ELITE RAILROAD, PRICED FOR THE MERGER TO WORK — RECORD REVENUE BUT MOSTLY FUEL, AT AN ALL-TIME HIGH) — base-case value ~$285 vs ~$303 today.

What to watch: A clean STB approval of the Norfolk Southern merger is the bull trigger — it unlocks the ~$2.75B of synergies and the compounder path north of $340, and we'd upgrade. What breaks the thesis is the opposite: the STB blocks or heavily conditions the deal, the ~$2.5B reverse-termination fee bites, and the stock re-rates back toward its standalone value in the mid-$200s. Secondary watch items: whether core pricing holds up as the fuel-surcharge tailwind fades, the operating-ratio trajectory ex-fuel, coal's structural decline (carloads -14%), and leverage rising from 2.5x toward 3.3x at merger close (with the buyback frozen).

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Infosys Limited (INFY) Q1 FY2027 — Infosys (INFY), India's ~$43B #2 IT-services giant, reported Q1 FY2027 (quarter ended June 30) on July 23 — and the NYSE ADR sits at a fresh 52-week low near $10.60, down ~65% from a $30 high last December. The headline looked strong: revenue ₹48,211 cr (~$5.08B) +14% YoY and net profit ₹7,769 cr (~$805M) +12.2%, with operating margin a resilient 21.1%. But in the currency the ADR actually earns — USD, constant-currency — revenue grew just 2.4%, profit fell 8.6% QoQ, and management CUT the top end of FY27 revenue guidance to 1.5–3.0% cc (from 1.5–3.5%) as discretionary spend stays subdued. The offsets: $3.6B in large-deal TCV (61% net new), AI-led revenue already 8.2%, a net-cash balance sheet, ~33% ROE, ~$3.7B FCF (~9% yield) and a ~5% dividend. The debate is whether generative AI deflates the labor-arbitrage model — or just makes it more productive. Our owner-earnings DCF centers near $14.50 vs the ~$10.60 price.

Infosys (INFY) is India's second-largest IT-services company — a ~$43B global outsourcer in Bengaluru that writes software, runs systems and now sells AI (via its Topaz platform) to the world's biggest banks, retailers and drugmakers, using ~328,000 mostly-India-based engineers. It trades in New York as a 1:1 ADR but reports in rupees. On July 23 it posted a Q1 FY2027 that split down the middle: revenue ₹48,211 cr (~$5.08B) up 14% and net profit ₹7,769 cr (~$805M) up 12.2% in rupees — yet only +2.4% revenue growth in constant-currency USD, with profit down 8.6% sequentially and EPS ~$0.20/ADR landing in line to soft. The stock, already down ~65% from a December high near $30, fell to a fresh 52-week low near $10.60 — because management trimmed the upper end of FY27 revenue guidance to 1.5–3.0% constant currency (from 1.5–3.5%), citing still-subdued discretionary spending. Two under-covered wrinkles drive the story. First, the rupee: it has weakened ~12% vs the dollar, which inflates the rupee headline and helps margins (costs are in rupees) but erodes what a USD ADR holder compounds — so the honest growth rate is low-single-digit, not 14%. Second, the AI question: AI-led work is already 8.2% of revenue and headcount is flat (328,062, −532 QoQ), which looks more like productivity than a pricing collapse — but if GenAI deflates deal sizes and revenue-per-employee, this labor-arbitrage model is structurally threatened. Against that, the fortress: ~$3.7B free cash flow (~9% yield), ~33% ROE, net cash ~$2.8B, a resilient 21.1% operating margin (guide held at 20–22%), $3.6B in large deals (61% net new), and a ~5% dividend plus buybacks. Our owner-earnings DCF (base ~$3.7B FCF; a 'slow' +2%/yr path and an 'AI-dividend' +6%/yr path; 9–11% discount; ADD ~$2.8B net cash; ÷~4.06B shares) centers near $14.50 vs ~$10.60 — roughly 37% upside, with even the slow case at an 11% discount landing at/above the price. Our call: BUY, 4/5 — a valuation call, not a growth call. The Street is a fence-sitting Hold (15B/21H/4S, ~$13 target, +23%); we differ, more bullish, because the crash appears to have priced in near-zero growth on a debt-free cash machine. The one risk to respect is a structural AI reset. Not financial advice.

THE CALL: BUY (4/5, A NET-CASH CASH MACHINE THE MARKET OVERSHOT — SLOW GROWTH AND A REAL AI-DEFLATION RISK, BUT ~37% UPSIDE TO FAIR VALUE WITH A ~5% DIVIDEND TO WAIT AND EVEN THE BEAR CASE AT/ABOVE THE PRICE) — base-case value ~$14.50 vs ~$10.60 today.

KEY METRICS:

- Revenue ₹48,211 cr (~$5.08B), +14% YoY in INR but only +2.4% YoY in constant-currency USD

- Net profit ₹7,769 cr (~$805M), +12.2% YoY but −8.6% QoQ; EPS ~$0.20/ADR, in line to soft vs est.

- Operating margin 21.1% (resilient); FY27 margin guide reaffirmed at 20–22%

- FY27 revenue-growth guidance CUT: upper end trimmed to 1.5–3.0% cc (from 1.5–3.5%), discretionary spend subdued

- Large-deal TCV $3.6B, 61% net new — the order book that refills a slow year

- AI-led revenue already 8.2% (Topaz); headcount flat at 328,062 (−532 QoQ), attrition ~13%

- Geography (cc): North America +3.2%, Europe +2.8%; led by financial services + life sciences

- Free cash flow ~$3.7B FY26 (~9% FCF yield); ROE ~33%; net cash ~$2.8B, near debt-free

- Capital return: ~$0.52/ADR dividend (~5% yield at $10.60) plus buybacks

- ADR 1:1; reports in INR, trades in USD; FX ~₹96.6/USD; rupee ~−12% YoY drags USD returns; ~4.06B shares

- Our owner-earnings DCF fair value ~$14.50 vs ~$10.60 ADR — BUY 4/5, ~37% upside, bear case ~$11

- Street consensus Hold (15B/21H/4S, 40 analysts), ~$13 avg target (+23%) — we're more bullish

What to watch: evidence the AI dividend is real rather than deflationary — constant-currency growth re-accelerating back toward mid-single-digits, the $3.6B large-deal book converting to revenue, headcount stabilizing while the 20–22% margin holds — would justify a higher-conviction upgrade; the risks to respect are proof of AI deflation (shrinking deal sizes, falling revenue-per-employee, client price concessions), continued rupee weakness eroding USD/ADR returns, and further guidance cuts, so watch constant-currency growth and pricing every quarter

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Rollins, Inc. (ROL) Q2 2026 — Rollins (ROL), the pest-control compounder behind Orkin, HomeTeam, Clark, Western and Fox, reported a rare Q2 2026 DOUBLE MISS: adjusted EPS of $0.32 missed the ~$0.34 estimate (though +6.7% YoY) and revenue of $1.079B came in light (still +7.9% YoY — its 99th straight quarter of growth). The real damage was margin: operating margin fell 110 bps to 18.7% and incremental EBITDA margin collapsed to ~6.5% as soft residential lead volume met a cost base built for faster growth. Organic growth slowed to 5.7% (residential organic just +3.6%; commercial +7.2%; termite +8.9%). The stock, already down ~40% from its ~$66 January high, gapped ~9% to a fresh 52-week low near $40. FCF was $166M (115% conversion), leverage sits at 1.0x, and the dividend was raised 11%. Our owner-earnings DCF lands fair value ~$42 — essentially in line with the price. Our call: HOLD.

Rollins (ROL) is one of the market's great compounders — the pest-control leader behind Orkin, HomeTeam, Clark, Western and Fox, serving 2.8 million customers with a stunning 99 consecutive quarters of revenue growth. But Q2 2026 delivered something it almost never does: a rare double miss. Adjusted EPS of $0.32 missed the ~$0.34 estimate (though still +6.7% YoY) and revenue of $1.079B came in light (+7.9% YoY). The real damage was margin — operating margin fell 110 bps to 18.7% and incremental EBITDA margin collapsed to ~6.5% as soft residential lead volume (consumer-initiated demand via search, digital and inbound calls) met a cost base built for faster growth. Organic growth slowed to 5.7% (residential organic just +3.6%; commercial +7.2%; termite +8.9%). The stock, already down ~40% from its ~$66 January high, gapped ~9% to a fresh 52-week low near $40. The balance sheet is a fortress — 1.0x leverage, 115% FCF conversion, dividend raised 11%, and the roll-up M&A engine still running ($117M of tuck-ins this quarter). So the debate flips: for years ROL was too expensive to touch; now a wonderful business is marked down. But our owner-earnings DCF lands fair value ~$42 — essentially in line with the ~$40 price, with no real margin of safety and a fresh growth-and-margin stumble. We're more cautious than the Street's ~$52 average target (a soft Hold, and one bank just cut it to a sell). Our call: HOLD, 3/5 — a wonderful business, finally fairly priced, as the algorithm stumbles. We'd get greedy in the mid-$30s, or on proof residential lead volumes have healed. Not financial advice.

THE CALL: HOLD (3/5, A WONDERFUL BUSINESS, FAIRLY PRICED, AS THE ALGORITHM STUMBLES — A RARE DOUBLE MISS WITH NO MARGIN OF SAFETY YET) — base-case value ~$42 vs ~$40 today.

What to watch: hard evidence the residential lead-generation softness was a one-quarter air pocket — lead volumes reaccelerating, residential organic growth climbing back toward high-single digits, and incremental margins snapping back as the cost reset bites — which would justify paying up for the compounder again and prompt an upgrade; the risk to respect is the demand softness proving structural (organic growth stuck in the low-single digits with margins staying compressed and M&A merely masking weak organics), which at ~32x earnings could re-rate the stock lower even after its 40% fall

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Badger Meter (BMI) Q2 2026 — Badger Meter (BMI), the debt-free leader in smart water metering (ORION/BEACON hardware + the BlueEdge software suite), reported a mixed Q2 2026: diluted EPS of $1.02 edged the ~$1.01 estimate but fell 13% YoY, on sales of $222.3M (-7% YoY vs last year's record $238.1M, +10% sequential). Operating margin slipped to 17.7% (-110 bps) and utility-water revenue fell ~8% YoY on uneven AMI project timing, though it rose ~8% sequentially and flow instrumentation grew 6%. Management guided full-year revenue (ex-acquisitions) to roughly flat, reiterated a long-term high-single-digit growth framework, raised the dividend 18% (a 33-year streak) and bought back $63M of stock in H1. The stock dropped ~13% on the print to ~$123 — now down ~40% from its $204 high and near a 52-week low. The catch: even after the fall, BMI trades ~28x earnings, and our owner-earnings DCF pegs fair value near $125 — essentially today's price. Our call: HOLD.

Badger Meter (BMI) is one of the market's beloved smart-water compounders — the debt-free leader in advanced water metering (ORION/BEACON) and the BlueEdge software suite utilities use to read, bill and manage water remotely, and a 33-year dividend-increase aristocrat. For years it traded like it, at 45-50x earnings and above $200. Then growth stalled. Q2 2026 was a 'beat' on a lowered bar: diluted EPS of $1.02 nudged the ~$1.01 estimate but fell 13% YoY, on sales of $222.3M — up 10% sequentially but down 7% versus last year's record $238.1M. Gross margin held at 40.8%, but operating margin slipped to 17.7% (-110 bps). The drag was utility water (-8% YoY, roughly -9% ex-acquisition) on the uneven ramp of large AMI projects, partly offset by +8% sequential growth, a 6% rise in flow instrumentation, and growing BlueEdge software. Crucially, management guided full-year revenue (ex-acquisitions) to roughly flat and framed the stall as project-timing phasing, not broken demand, reiterating a long-term high-single-digit growth framework at its first Investor Day. The market wasn't convinced: the stock fell ~13% on the print to ~$123, now down ~40% from its $204 high and near a 52-week low. Balance sheet is pristine — ~$96M net cash, zero debt, an untapped $150M revolver — and management leaned into the drop, raising the dividend 18% to $0.40/qtr (33rd straight year) and repurchasing $63M of stock in H1. So the debate isn't quality; it's whether the premium has reset far enough. Even after the fall, BMI trades ~28x earnings. Our owner-earnings DCF — a normalized ~$135M base, a compounder-leaning blend at an 8.5% quality discount — lands fair value near $125, essentially today's price. The reset removed the reckless overvaluation but left no margin of safety yet, with revenue still shrinking. Our call: HOLD, 3/5 — a great company reset to a fair price. We're more cautious than the Street, which agrees it's roughly a Hold yet carries a ~$155 average target (~25% upside). Own it for the quality, add on real weakness toward $100, and watch the second-half AMI ramp. Not financial advice.

THE CALL: HOLD (3/5, A GREAT COMPANY WHOSE PREMIUM FINALLY RESET TO FAIR VALUE — QUALITY INTACT, NO MARGIN OF SAFETY YET) — base-case value ~$125 vs ~$123 today.

What to watch: hard evidence the AMI ramp is real — utility-water revenue growing year over year again and the BlueEdge software mix climbing, which would validate the high-single-digit compounder path and justify paying up toward the mid-$100s and an upgrade; the risk to respect is another quarter or two of AMI project slippage or margin erosion, which — even after a 40% fall, at ~28x earnings on a still-shrinking top line — could push the stock back toward the low $100s before it finds a floor

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Lockheed Martin (LMT) Q2 2026 — Lockheed Martin (LMT), the world's largest pure-play defense prime (F-35, PAC-3/THAAD missile defense, Sikorsky, Space), reported a headline-grabbing Q2 2026: GAAP diluted EPS of $7.94 beat the ~$7.22 estimate (+444% YoY) on revenue of $20.1B (+11%), with free cash flow of $2.9B (vs -$150M a year ago) and every segment profitable. But the +444% is mostly optics — it laps ~$1.6B (~$5/sh) of 2025 program charges; underlying EPS grew ~20%. The real story: a RECORD $230B backlog (~2.9x sales) and a missile-defense supercycle — Missiles & Fire Control grew +19% (14.5% margin), and a $35B THAAD award nearly doubled that segment's backlog to ~$88B. Management RAISED full-year 2026 guidance across the board (sales $79.8-81.8B, EPS $29.95-30.65, FCF $7.0-7.2B). The stock popped ~6% to ~$543, still ~21% below its $692 high. Our owner-earnings DCF (normalized ~$7.0B FCF; base-defense vs Golden Dome paths; 8-10% discount) lands fair value ~$585 — modestly above the price. Our call: BUY, 3/5.

Lockheed Martin (LMT) is the world's largest pure-play defense contractor — the F-35 stealth fighter, PAC-3 and THAAD missile interceptors, Sikorsky Black Hawk helicopters, and national-security satellites. Q2 2026 looked like a blowout: GAAP diluted EPS of $7.94 crushed the ~$7.22 estimate (+444% YoY), revenue rose 11% to $20.1B, free cash flow swung to $2.9B (from -$150M a year ago), every segment was profitable, and management RAISED full-year 2026 guidance across the board (sales $79.8-81.8B, EPS $29.95-30.65, FCF $7.0-7.2B). But the +444% headline is mostly an illusion: it laps ~$1.6B (~$5/share) of one-time 2025 program charges — strip those out and underlying EPS grew a still-solid ~20%. The genuinely important story is durability: a RECORD $230B backlog (~2.9x annual sales), and a missile-defense supercycle showing up in hard numbers — Missiles & Fire Control grew +19% with a 14.5% margin, and a $35B THAAD award nearly doubled that segment's backlog to ~$88B ('Golden Dome' / munitions replenishment). The catch is real: Lockheed is a serial charge-taker on fixed-price programs, buybacks are paused ($0 in H1 vs $1.25B a year ago), and F-35 deliveries collapsed to 19 (from 50). Our owner-earnings DCF — normalizing the flattered ~$8.7B TTM cash to ~$7.0B, weighting a base-defense path (+4%) more than an optimistic Golden Dome path (+7%), at an 8-10% discount — lands fair value near $585, modestly above the ~$543 price. Our call: BUY, 3/5 — reasonable value on a record backlog, a blue-chip fortress finally on sale, tempered by the charge history and the paused buyback. We're constructive but more conservative than the Street's ~$623 average target (Buy, 21 of 37 analysts). Own it for the backlog, add on weakness toward the low $500s, and mind the charge risk. Not financial advice.

THE CALL: BUY (3/5, REASONABLE VALUE ON A RECORD BACKLOG — A BEAT-AND-RAISE WHERE THE +444% HEADLINE HIDES THE REAL STORY) — base-case value ~$585 vs ~$543 today.

What to watch: two or three clean, charge-free quarters in a row, the F-35 delivery pace normalizing, and continued Golden Dome / munitions orders flooding the backlog would prove execution has genuinely turned and move us from a 3 to a 4; the risk to respect is another surprise reach-forward charge on a fixed-price program (Lockheed's recurring Achilles' heel) or missile-defense budget momentum stalling, either of which could turn today's reasonable multiple back into a value trap

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

RTX Corporation (RTX) Q2 2026 — RTX Corporation (RTX), the aerospace-and-defense prime (Collins Aerospace, Pratt & Whitney, Raytheon), reported a blowout Q2 2026: adjusted EPS of $1.89 crushed the ~$1.66 estimate (+21% YoY) on sales of $24.7B (+14%, +16% organic), operating margin expanded across all three segments, and free cash flow swung to +$2.9B (from -$72M a year ago). Management RAISED full-year 2026 guidance across the board — adjusted sales to $95-96B, organic growth to 8-9%, adjusted EPS to $7.10-$7.25, and FCF to $8.5-$8.75B — on a record $289B backlog (+22%; $170B commercial / $119B defense). Segments: Collins $8.2B (+8%, 16.7% margin), Pratt $8.9B (+16%, 8.3% margin), Raytheon $8.3B (+18%, 12.6% margin). Yet the stock (~$195, +0.6%) faded a +4% pre-market pop — and fell ~4% on the last beat-and-raise. At ~27x forward earnings and ~30x FCF, even our compounder-leaning owner-earnings DCF lands near $190 — right on top of the price. Our call: HOLD.

RTX is one of the world's two dominant aerospace-and-defense primes — a ~$262B company born from the 2020 Raytheon–United Technologies merger, balanced almost perfectly across three businesses: Collins Aerospace (avionics & systems), Pratt & Whitney (jet engines — the GTF and the F135 that powers the F-35), and Raytheon (Patriot, AMRAAM, Standard Missile). Q2 2026 was a genuine blowout: adjusted EPS of $1.89 beat the ~$1.66 estimate (+21% YoY), sales rose 14% to $24.7B (+16% organic — nearly $2B above expectations), margins expanded across all three segments, and free cash flow swung to +$2.9B from a small outflow a year ago. For the second time this year, management RAISED full-year guidance across the board — adjusted sales to $95-96B, organic growth to 8-9%, adjusted EPS to $7.10-$7.25, and FCF to $8.5-$8.75B — backed by a record $289B backlog (+22%), ~3x annual sales and split $170B commercial / $119B defense. The drivers: commercial aftermarket (Collins +10%, Pratt +25%) as airlines fly older jets hard, a defense super-cycle (Raytheon +18% on Patriot/AMRAAM/SM), and a GTF aftermarket wave just starting (800+ orders YTD, 8,000+ engine backlog). So the debate isn't quality — it's price. The stock trades near $195, ~27x forward earnings and ~30x FCF, and it faded a +4% pre-market pop to roughly flat (it fell ~4% on the Q1 beat-and-raise). Even giving RTX the optimistic compounder path (10%->4% FCF growth) AND a fair 9% discount rate, our owner-earnings DCF lands near $190 — right on top of the price; the steady path is worth less ($150 at 9%). A wonderful, all-weather franchise with no margin of safety. Our call: HOLD, 3/5. We're not sellers of quality this good and this well-positioned, but at ~27x we wouldn't chase it — and we're a touch more cautious than the Street's bullish ~$220 average target (Buy, 18 of 26 analysts, though most targets predate this morning's raise). Own it for the quality, add on real weakness toward the mid-$160s, and watch Pratt's margin and the GTF aftermarket. Not financial advice.

THE CALL: HOLD (3/5, FIRING ON ALL CYLINDERS, PRICED AT FAIR VALUE — A BLOWOUT BEAT-AND-RAISE WITH NO MARGIN OF SAFETY) — base-case value ~$190 vs ~$195 today.

What to watch: hard evidence the GTF aftermarket is inflecting and Pratt's segment margin is climbing toward the teens — which would unlock the compounder path (fair value north of $215) and prompt an upgrade; the risks to respect are a defense-budget air-pocket, escalating tariffs (~$500M IEEPA exposure), or another Pratt powder-metal reserve increase, any of which could re-rate a full ~27x multiple

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Thermo Fisher Scientific (TMO) Q2 2026 — Thermo Fisher Scientific (TMO) — the 'picks-and-shovels' arms dealer of the life-science and diagnostics industry — reported a strong Q2 2026: adjusted EPS of $6.03 beat the ~$5.71 estimate (+13% YoY) on revenue of $11.99B (+10% reported, +5% organic — a beat), with adjusted operating margin EXPANDING 90 bps to 22.8% and free cash flow surging 52% to $1.68B (a 14% margin). GAAP EPS was $4.68 (+9%). Crucially, organic growth reaccelerated from ~1% in Q1 to 5% in Q2 — the clearest sign yet that the multi-year end-market slump is bottoming. The stock, cut from a ~$639 high (Jan) to a ~$438 low (May) — a 31% de-rating — trades near $530 (up ~4% on the print), about 21x forward earnings, near the low end of its decade. Our owner-earnings DCF centers fair value near $560 (base/recovery ~$531, right at the price; bull/compounder path ~$659), a touch below the Street's ~$585 (Buy, 37 of 42 analysts). Our call: BUY, 4/5 — a wide-moat compounder finally on sale as fundamentals inflect, tempered by real risks: only ~2-3% structural organic growth, $38.5B net debt (3.5x EBITDA), and NIH/academic-funding, China, and tariff overhangs.

Thermo Fisher Scientific (TMO) is one of the highest-quality businesses in all of healthcare — the arms dealer of life science. It doesn't bet on any single drug; it sells the instruments, reagents, consumables, and outsourced clinical-trial and manufacturing services that virtually every pharma, biotech, academic, and diagnostics lab on earth depends on, with more than 80% of revenue recurring. Yet from January to spring, the stock fell from a ~$639 high to a ~$438 low — a brutal 31% de-rating — on fears about NIH/academic research funding, China, and tariffs, even though earnings never actually fell. Q2 2026 is the quarter the tide turned: adjusted EPS of $6.03 beat the ~$5.71 estimate (+13% YoY), revenue of $11.99B rose 10% (and 5% organically — a beat), adjusted operating margin EXPANDED 90 bps to 22.8% despite tariff and China pressure, and free cash flow jumped 52% to $1.68B. Most important, organic growth reaccelerated from ~1% in Q1 to 5% in Q2. Through six months, adjusted EPS is $11.47 (+9%) and free cash flow is $2.5B (+69%). The four segments: Laboratory Products & Biopharma Services ($6.69B, 56% of sales, +12%), Life Sciences Solutions ($2.82B, +13%, 37% margin), Analytical Instruments ($1.85B, +7%), and Specialty Diagnostics ($1.21B, +6%). TMO is a serial acquirer (PPD, Patheon, Clario) that compounds double digits per share despite modest organic growth, and it repurchased $1.0B of stock in Q2 while announcing a microbiology divestiture. At ~$530, ~21x forward earnings near the low end of its decade, our owner-earnings DCF centers fair value near $560 — base/recovery case ~$531 (right at the price), bull/compounder case ~$659 — versus the Street's ~$585 (Buy). Our honest, model-driven call: BUY, 4/5. A world-class compounder, marked down on sentiment, with growth and margins inflecting — quality finally on sale. But we respect the risks: only ~2-3% structural organic growth, $38.5B net debt, and lingering policy/China overhangs. Accumulate here, and add aggressively on weakness toward the high-$400s. Not financial advice.

THE CALL: BUY (4/5, A WIDE-MOAT COMPOUNDER, QUALITY FINALLY ON SALE — INFLECTING GROWTH AT A REASONABLE PRICE) — base-case value ~$560 vs ~$530 today.

What to watch: the organic recovery proving durable — another quarter or two of 5%+ organic growth with biopharma demand firming and China stabilizing — which would validate the compounder path and justify a higher target and upgrade; the risks to respect are organic growth stalling back toward zero, a fresh cut to NIH/academic research funding or a China setback, and the $38.5B net debt (3.5x EBITDA) constraining the buyback

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.